论文部分内容阅读
目的 :评价头孢地嗪和莫敌 (进口头孢地嗪 )治疗下呼吸道感染的疗效和安全性。方法 :采用随机双盲对照多中心分组研究方法 ,每组 30例 ,两药剂量均为 2 g/次 ,q12h ,静滴 ,疗程 7～ 14d。 结果 :头孢地嗪组和莫敌组的临床疗效痊愈率分别为 45 .2 %和 5 4.8% ,有效率分别为 90 .3%和 80 .6 % ,细菌清除率分别为 93.3%和 95 .4% ,不良反应发生率分别为 3.2 %和 6 .4% ,无统计学显著性差异。结论 :头孢地嗪治疗下呼吸道感染安全、有效 ,与莫敌生物等效。
OBJECTIVE: To evaluate the efficacy and safety of cefodizime and prophylaxis (cefodizime) in the treatment of lower respiratory tract infections. Methods: A randomized, double-blind, controlled, multicentre study was conducted in 30 patients in each group. The doses of both drugs were 2 g / time, q12h, and intravenous infusion for 7-14 days. Results: The cure rates of cefodizime and modiquat were 45.2% and 58.8% respectively, the effective rates were 90.3% and 80.6% respectively, and the bacterial clearance rates were 93.3% and 95% respectively. 4%, the incidence of adverse reactions were 3.2% and 6.4%, no statistically significant difference. Conclusion: Cefodizime is safe, effective and bioequivalent to lower respiratory tract infection.